pancreatic adenosquamous carcinoma
pancreatic adenosquamous carcinoma
Explore linked clinical trials. Standard reference: MONDO:00056148 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | pancreatic acinar cell carcinoma, pancreatic adenosquamous carcinoma, squamous cell carcinoma of pancreas | Recruiting | Phase 2 | 2026-10-08 | NCT04858334 | |
| Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma, pancreatic neoplasm | Recruiting | Phase 3 | 2026-10-02 | NCT07491445 | |
| Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma, pancreatic neoplasm | Recruiting | Phase 3 | 2026-09-28 | NCT07621718 | |
| Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma, pancreatic neoplasm | Recruiting | Phase 3 | 2026-09-08 | NCT07805954 | |
| Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic adenosquamous carcinoma, pancreatic neoplasm | Active, not recruiting | Phase 3 | 2026-09-04 | NCT04340141 | |
| Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma, pancreatic neoplasm | Recruiting | Phase 1 | 2026-08-26 | NCT04157127 | |
| Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, cystic, mucinous, and serous neoplasm, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, mucinous adenocarcinoma, neoplasm, pancreas disorder, pancreatic adenosquamous carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-06-24 | NCT07665684 | |
| The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Pancreatic Carcinoma, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic acinar cell carcinoma, pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm, squamous cell carcinoma of pancreas | Active, not recruiting | Phase 2 / Phase 3 | 2026-01-07 | NCT06115499 |